{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:42:59Z","timestamp":1792611779784,"version":"4.5.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiothorac Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Introduction of Bare Metal Stents (BMS) was itself a revolutionary step in the history of the medical industry; however, Drug Eluting Stents (DES) maintained its superiority over BMS in every aspect from restenosis rate to late lumen loss. The reason behind the magnanimous position of the DES in the stent market is the degree of improvement with which it evolves. New and better stents come into the market every year, surpassing their predecessors by many folds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Literature review<\/jats:title>\n                    <jats:p>This review paper discusses the journey of DES with supporting clinical trials in detail. In the first generation, there were stainless-steel stents with thicker coatings. Although they had superior results compared to BMS, there was still room for improvement. Afterward came the second-generation stents, which had superior metal platforms with thinner struts and thin coatings. The drugs were also changed from Paclitaxel and Sirolimus to Zotrolimus and Everolimus. These stents performed best; however, there was an issue of permanent coating, which remained intact over the stent surface after complete drug elution and started to cause issues in longer-term studies. Hence, an improved version of DES was introduced to these permanent coatings called the third generation of drug eluting stents, which initially utilized biodegradable polymer and ultimately moved towards polymer free drug coatings. This generation has introduced a unique amalgam of technologies to achieve its polymer free coatings; however, researchers have numerous prospects of growth in this field. This review paper highlights the major coups of stent technology evolution from BMS to DES, from thick polymeric coatings to thin coatings and\u00a0from durable polymers to polymer free DES.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In conclusion, though the medical industry promptly accepted BMS as the best treatment option for cardiovascular diseases; however, DES has provided even better results than BMS. In DES, the first and second generation has ruled the technology for many years and are still on the shelves. Still, the issues aroused due to durable polymer shifted the attention towards biodegradable drug eluting stents, the third generation growing rapidly. But the scientific community has not restricted themselves and is investigating bioresorbable stents that completely eliminate the polymer intervention in drug eluting stent technology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13019-022-01812-y","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T08:04:08Z","timestamp":1649059448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Evolutionary perspective of drug eluting stents: from thick polymer to polymer free approach"],"prefix":"10.1186","volume":"17","author":[{"given":"Sadia","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3829-8215","authenticated-orcid":false,"given":"Murtaza Najabat","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakhtawar","family":"Ghafoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"1812_CR1","unstructured":"Tomberli B, Mattesini A, Baldereschi GI, Di Mario C. A brief history of coronary artery stents. Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)."},{"issue":"8","key":"1812_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1056\/NEJM199408253310801","volume":"331","author":"PW Serruys","year":"1994","unstructured":"Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. New Engl J Med. 1994;331(8):489\u201395.","journal-title":"New Engl J Med"},{"issue":"2","key":"1812_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0735-1097(95)00473-4","volume":"27","author":"C Macaya","year":"1996","unstructured":"Macaya C, Serruys PW, Ruygrok P, Suryapranata H, Mast G, Klugmann S, et al. Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. Benestent Study Group. J Am Coll Cardiol. 1996;27(2):255\u201361.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1812_CR4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1540-8183.1994.tb00498.x","volume":"7","author":"RA Schatz","year":"1994","unstructured":"Schatz RA. Insights from the STRESS trial. STent REStenosis Study. J Interv Cardiol. 1994;7(6):575\u201380.","journal-title":"J Interv Cardiol"},{"issue":"7","key":"1812_CR5","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S0002-9149(98)00004-6","volume":"81","author":"CJ George","year":"1998","unstructured":"George CJ, Baim DS, Brinker JA, Fischman DL, Goldberg S, Holubkov R, et al. One-year follow-up of the stent restenosis (STRESS I) study 11. This study was supported in part by Johnson & Johnson Interventional Systems (Cordis), Incorporated, Warren, New Jersey. Am J Cardiol. 1998;81(7):860\u20135.","journal-title":"Am J Cardiol"},{"issue":"2","key":"1812_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0735-1097(97)00511-1","volume":"31","author":"MP Savage","year":"1998","unstructured":"Savage MP, Fischman DL, Rake R, Leon MB, Schatz RA, Penn I, et al. Efficacy of coronary stenting versus balloon angioplasty in small coronary arteries. Stent Restenosis Study (STRESS) Investigators. J Am Coll Cardiol. 1998;31(2):307\u201311.","journal-title":"J Am Coll Cardiol"},{"issue":"47","key":"1812_CR7","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1093\/eurheartj\/ehv511","volume":"36","author":"RA Byrne","year":"2015","unstructured":"Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gr\u00fcntzig Lecture ESC 2014. Eur Heart J. 2015;36(47):3320\u201331.","journal-title":"Eur Heart J"},{"issue":"11","key":"1812_CR8","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1001\/jamacardio.2018.3573","volume":"3","author":"DJ Kereiakes","year":"2018","unstructured":"Kereiakes DJ. The myths of the bare-metal stent. JAMA Cardiol. 2018;3(11):1039\u201340.","journal-title":"JAMA Cardiol"},{"issue":"7","key":"1812_CR9","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.amjcard.2016.06.061","volume":"118","author":"JA Rymer","year":"2016","unstructured":"Rymer JA, Harrison RW, Dai D, Roe MT, Messenger JC, Anderson HV, et al. Trends in bare-metal stent use in the United States in patients aged \u2265 65 years (from the CathPCI Registry). Am J Cardiol. 2016;118(7):959\u201366.","journal-title":"Am J Cardiol"},{"issue":"2","key":"1812_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ccd.22509","volume":"76","author":"IM Singh","year":"2010","unstructured":"Singh IM, Filby SJ, El Sakr F, Gorodeski EZ, Lincoff AM, Ellis SG, et al. Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis. Catheter Cardiovasc Interv. 2010;76(2):257\u201362.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"12","key":"1812_CR11","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.amjcard.2009.02.011","volume":"103","author":"A Villa","year":"2009","unstructured":"Villa A, Arnold R, S\u00e1nchez PL, Gimeno F, Ramos B, Cantero T, et al. Comparison of neointimal hyperplasia with drug-eluting stents versus bare metal stents in patients undergoing intracoronary bone-marrow mononuclear cell transplantation following acute myocardial infarction. Am J Cardiol. 2009;103(12):1651\u20136.","journal-title":"Am J Cardiol"},{"issue":"13","key":"1812_CR12","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1056\/NEJMoa1607991","volume":"375","author":"KH B\u00f8naa","year":"2016","unstructured":"B\u00f8naa KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nyg\u00e5rd O, et al. Drug-eluting or bare-metal stents for coronary artery disease. New Engl J Med. 2016;375(13):1242\u201352.","journal-title":"New Engl J Med"},{"issue":"3","key":"1812_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40204-018-0097-y","volume":"7","author":"S Borhani","year":"2018","unstructured":"Borhani S, Hassanajili S, Ahmadi Tafti SH, Rabbani S. Cardiovascular stents: overview, evolution, and next generation. Prog Biomater. 2018;7(3):175\u2013205.","journal-title":"Prog Biomater"},{"key":"1812_CR14","first-page":"1418","volume-title":"Corporate considerations on biomaterials and medical devices: case studies in regulation and reimbursement. Biomaterials science","author":"GD Baura","year":"2013","unstructured":"Baura GD. Corporate considerations on biomaterials and medical devices: case studies in regulation and reimbursement. Biomaterials science. Elsevier; 2013. p. 1418\u201324."},{"issue":"2","key":"1812_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2147\/vhrm.2007.3.2.191","volume":"3","author":"A Abizaid","year":"2007","unstructured":"Abizaid A. Sirolimus-eluting coronary stents: a review. Vasc Health Risk Manag. 2007;3(2):191\u2013201.","journal-title":"Vasc Health Risk Manag"},{"key":"1812_CR16","unstructured":"Alrabiah H, Stagner WC, Gaddam S, Parmar R, Ghanta AK, Abdelgalil AA, et al. Profiles of drug substances, excipients and related methodology. 2014."},{"issue":"7","key":"1812_CR17","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s10856-009-3705-5","volume":"20","author":"M Boden","year":"2009","unstructured":"Boden M, Richard R, Schwarz MC, Kangas S, Huibregtse B, Barry JJ. In vitro and in vivo evaluation of the safety and stability of the TAXUS paclitaxel-eluting coronary stent. J Mater Sci Mater Med. 2009;20(7):1553\u201362.","journal-title":"J Mater Sci Mater Med"},{"issue":"1","key":"1812_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1161\/01.CIR.0000047700.58683.A1","volume":"107","author":"E Grube","year":"2003","unstructured":"Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107(1):38\u201342.","journal-title":"Circulation"},{"issue":"15","key":"1812_CR19","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1161\/CIRCULATIONAHA.109.849877","volume":"120","author":"S Silber","year":"2009","unstructured":"Silber S, Colombo A, Banning AP, Hauptmann K, Drzewiecki J, Grube E, et al. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Circulation. 2009;120(15):1498\u2013504.","journal-title":"Circulation"},{"issue":"10","key":"1812_CR20","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1001\/jama.294.10.1215","volume":"294","author":"GW Stone","year":"2005","unstructured":"Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294(10):1215\u201323.","journal-title":"JAMA"},{"issue":"8","key":"1812_CR21","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jama.295.8.895","volume":"295","author":"M-C Morice","year":"2006","unstructured":"Morice M-C, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA. 2006;295(8):895\u2013904.","journal-title":"JAMA"},{"key":"1812_CR22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/ehjci\/jes025","volume":"13","author":"J Guti\u00e9rrez-Chico","year":"2012","unstructured":"Guti\u00e9rrez-Chico J, Alegr\u00eda-Barrero E, Teijeiro R, Chan PH, Tsujioka H, Silva R, et al. Optical coherence tomography: from research to practice. Eur Heart J Cardiovasc Imaging. 2012;13:370\u201384.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"23","key":"1812_CR23","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1161\/01.CIR.103.23.2816","volume":"103","author":"A Kastrati","year":"2001","unstructured":"Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann FJ, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation. 2001;103(23):2816\u201321.","journal-title":"Circulation"},{"issue":"8","key":"1812_CR24","doi-asserted-by":"publisher","first-page":"e008024","DOI":"10.1161\/CIRCINTERVENTIONS.119.008024","volume":"12","author":"JF Iglesias","year":"2019","unstructured":"Iglesias JF, Heg D, Roffi M, T\u00fcller D, Noble S, Muller O, et al. Long-term effect of ultrathin-strut versus thin-strut drug-eluting stents in patients with small vessel coronary artery disease undergoing percutaneous coronary intervention: a subgroup analysis of the BIOSCIENCE randomized trial. Circ Cardiovasc Intervent. 2019;12(8):e008024.","journal-title":"Circ Cardiovasc Intervent"},{"issue":"8","key":"1812_CR25","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S0735-1097(03)00119-0","volume":"41","author":"J Pache","year":"2003","unstructured":"Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003;41(8):1283\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1812_CR26","first-page":"16","volume":"4","author":"B AL-Mangour","year":"2013","unstructured":"AL-Mangour B, Mongrain R, Yue S. Coronary stents fracture: an engineering approach (review). Mater Sci Appl. 2013;4(10):16.","journal-title":"Mater Sci Appl"},{"key":"1812_CR27","doi-asserted-by":"crossref","unstructured":"Chen C-H, Kirtane AJ. 6-Stents, restenosis, and stent thrombosis. In: Kern MJ, Sorajja P, Lim MJ, editors. The interventional cardiac catheterization handbook (Fourth Edition): Elsevier; 2018. p. 179\u201399.","DOI":"10.1016\/B978-0-323-47671-3.00006-5"},{"key":"1812_CR28","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1517\/14656566.2014.948844","volume":"15","author":"E Guerra","year":"2014","unstructured":"Guerra E, Byrne R, Kastrati A. Pharmacological inhibition of coronary restenosis: systemic and local approaches. Expert Opin Pharmacother. 2014;15:2155\u201371.","journal-title":"Expert Opin Pharmacother"},{"issue":"7\u20138","key":"1812_CR29","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1016\/S0041-1345(01)02369-7","volume":"33","author":"B Nashan","year":"2001","unstructured":"Nashan B. The role of certican (everolimus, rad) in the many pathways of chronic rejection. Transplant Proc. 2001;33(7\u20138):3215\u201320.","journal-title":"Transplant Proc"},{"issue":"12","key":"1812_CR30","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1093\/neuonc\/nov152","volume":"17","author":"JP MacKeigan","year":"2015","unstructured":"MacKeigan JP, Krueger DA. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. Neuro Oncol. 2015;17(12):1550\u20139.","journal-title":"Neuro Oncol"},{"issue":"13","key":"1812_CR31","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","volume":"123","author":"K Kolandaivelu","year":"2011","unstructured":"Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich K-L, Giddings VL, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011;123(13):1400\u20139.","journal-title":"Circulation"},{"issue":"7","key":"1812_CR32","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S0142-9612(01)00297-6","volume":"23","author":"AL Lewis","year":"2002","unstructured":"Lewis AL, Tolhurst LA, Stratford PW. Analysis of a phosphorylcholine-based polymer coating on a coronary stent pre- and post-implantation. Biomaterials. 2002;23(7):1697\u2013706.","journal-title":"Biomaterials"},{"issue":"8","key":"1812_CR33","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","volume":"65","author":"M Valgimigli","year":"2015","unstructured":"Valgimigli M, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo G, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015;65(8):805.","journal-title":"J Am Coll Cardiol"},{"key":"1812_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2174\/1389557514666140530093620","volume":"14","author":"I Neamtu","year":"2014","unstructured":"Neamtu I, Chiriac A, Ghilan A, Nita L, Balan V, Nistor M. Current concepts on cardiovascular stent devices. Mini Rev Med Chem. 2014;14:505\u201336.","journal-title":"Mini Rev Med Chem"},{"issue":"5","key":"1812_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1540-8183.2006.00184.x","volume":"19","author":"DE Kandzari","year":"2006","unstructured":"Kandzari DE, Leon MB. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent. J Interv Cardiol. 2006;19(5):405\u201313.","journal-title":"J Interv Cardiol"},{"issue":"8","key":"1812_CR36","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1161\/CIRCULATIONAHA.105.591206","volume":"114","author":"J Fajadet","year":"2006","unstructured":"Fajadet J, Wijns W, Laarman G-J, Kuck K-H, Ormiston J, M\u00fcnzel T, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;114(8):798\u2013806.","journal-title":"Circulation"},{"issue":"5","key":"1812_CR37","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jcin.2010.12.014","volume":"4","author":"DE Kandzari","year":"2011","unstructured":"Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurbel PA, Fitzgerald PJ, et al. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. JACC Cardiovasc Interv. 2011;4(5):543.","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"1812_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/vhrm.2008.04.01.31","volume":"4","author":"I Sheiban","year":"2008","unstructured":"Sheiban I, Villata G, Bollati M, Sillano D, Lotrionte M, Biondi-Zoccai G. Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V). Vasc Health Risk Manag. 2008;4(1):31\u20138.","journal-title":"Vasc Health Risk Manag"},{"issue":"4","key":"1812_CR39","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.jcin.2015.12.076","volume":"9","author":"HA Sharar","year":"2016","unstructured":"Sharar HA, Katus HA, Bekeredjian R. CRT-200.44 bail-out SYNERGY stent implantation in complex coronary artery lesions. JACC Cardiovasc Interv. 2016;9(4):S16.","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"1812_CR40","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1111\/j.1540-8183.2009.00450.x","volume":"22","author":"N Ding","year":"2009","unstructured":"Ding N, Pacetti SD, Tang F-W, Gada M, Roorda W. XIENCE V\u2122 stent design and rationale. J Interv Cardiol. 2009;22(1):S18\u201327.","journal-title":"J Interv Cardiol"},{"issue":"5","key":"1812_CR41","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.ahj.2012.08.010","volume":"164","author":"R Diletti","year":"2012","unstructured":"Diletti R, Serruys PW, Farooq V, Sudhir K, Dorange C, Miquel-Hebert K, et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J. 2012;164(5):654\u201363.","journal-title":"Am Heart J"},{"issue":"5","key":"1812_CR42","doi-asserted-by":"publisher","first-page":"e554","DOI":"10.4244\/EIJ-D-17-00796","volume":"14","author":"B Xu","year":"2018","unstructured":"Xu B, Yang Y, Han Y, Huo Y, Wang L, Qi X, et al. Comparison of everolimus-eluting bioresorbable vascular scaffolds and metallic stents: three-year clinical outcomes from the ABSORB China randomised trial. EuroIntervention. 2018;14(5):e554\u201361.","journal-title":"EuroIntervention"},{"issue":"3","key":"1812_CR43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s12928-015-0366-9","volume":"31","author":"M Natsuaki","year":"2016","unstructured":"Natsuaki M, Morimoto T, Yamamoto E, Shiomi H, Furukawa Y, Abe M, et al. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. Cardiovasc Interv Ther. 2016;31(3):196\u2013209.","journal-title":"Cardiovasc Interv Ther"},{"issue":"7\u20138","key":"1812_CR44","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/BF03091792","volume":"18","author":"MWZ Basalus","year":"2010","unstructured":"Basalus MWZ, Tandjung K, van Houwelingen KG, Stoel MG, de Man FHAF, Louwerenburg JW, et al. TWENTE study: the real-world endeavor resolute versus xience V drug-eluting stent study in twente: study design, rationale and objectives. Neth Heart J. 2010;18(7\u20138):360\u20134.","journal-title":"Neth Heart J"},{"issue":"10059","key":"1812_CR45","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/S0140-6736(16)32050-5","volume":"388","author":"PW Serruys","year":"2016","unstructured":"Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carri\u00e9 D, Piek JJ, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016;388(10059):2479\u201391.","journal-title":"Lancet"},{"key":"1812_CR46","first-page":"149","volume":"7","author":"J Bennett","year":"2013","unstructured":"Bennett J, Dubois C. A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease. Biologics Targets Ther. 2013;7:149\u201359.","journal-title":"Biologics Targets Ther"},{"issue":"23","key":"1812_CR47","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1016\/j.jcin.2017.06.070","volume":"10","author":"CR Kelly","year":"2017","unstructured":"Kelly CR, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, et al. Long-term safety and efficacy of platinum chromium everolimus-eluting stents in coronary artery disease: 5-year results from the PLATINUM trial. JACC Cardiovasc Interv. 2017;10(23):2392\u2013400.","journal-title":"JACC Cardiovasc Interv"},{"issue":"8","key":"1812_CR48","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/eurheartj\/ehp044","volume":"30","author":"RA Byrne","year":"2009","unstructured":"Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J. 2009;30(8):923\u201331.","journal-title":"Eur Heart J"},{"issue":"5","key":"1812_CR49","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ihj.2013.08.031","volume":"65","author":"AB Mehta","year":"2013","unstructured":"Mehta AB, Chandra P, Dalal J, Shetty P, Desai D, Chocklingam K, et al. One-year clinical outcomes of BioMatrix\u2122-Biolimus A9\u2122 eluting stent: the e-BioMatrix multicenter post marketing surveillance registry in India. Indian Heart J. 2013;65(5):593\u20139.","journal-title":"Indian Heart J"},{"key":"1812_CR50","first-page":"100472","volume":"26","author":"IBA Menown","year":"2020","unstructured":"Menown IBA, Mamas MA, Cotton JM, Hildick-Smith D, Eberli FR, Leibundgut G, et al. First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: THE Biomatrix Alpha\u2122 registry. Int J Cardiol Heart Vasc. 2020;26:100472.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"9","key":"1812_CR51","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.3390\/ijms17091490","volume":"17","author":"A Chisari","year":"2016","unstructured":"Chisari A, Pistritto AM, Piccolo R, La Manna A, Danzi GB. The ultimaster biodegradable-polymer sirolimus-eluting stent: an updated review of clinical evidence. Int J Mol Sci. 2016;17(9):1490.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1812_CR52","doi-asserted-by":"publisher","first-page":"541","DOI":"10.4244\/EIJY14M08_06","volume":"11","author":"E Barbato","year":"2015","unstructured":"Barbato E, Salinger-Martinovic S, Sagic D, Beleslin B, Vrolix M, Neskovic AN, et al. A first-in-man clinical evaluation of Ultimaster, a new drug-eluting coronary stent system: CENTURY study. EuroIntervention. 2015;11(5):541\u20138.","journal-title":"EuroIntervention"},{"issue":"6","key":"1812_CR53","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.carrev.2016.04.001","volume":"17","author":"VA Jim\u00e9nez","year":"2016","unstructured":"Jim\u00e9nez VA, I\u00f1iguez A, Baz JA, Vald\u00e9s M, Ortiz A, Vuilliomenet A, et al. A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: the CENTURY II high risk ACS substudy. Cardiovasc Revasc Med. 2016;17(6):355\u201361.","journal-title":"Cardiovasc Revasc Med"},{"issue":"19","key":"1812_CR54","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.jacc.2012.09.004","volume":"60","author":"GW Stone","year":"2012","unstructured":"Stone GW, Abizaid A, Silber S, Dizon JM, Merkely B, Costa RA, et al. Prospective, randomized, multicenter evaluation of a polyethylene terephthalate micronet mesh-covered stent (MGuard) in st-segment elevation myocardial infarction: the MASTER trial. J Am Coll Cardiol. 2012;60(19):1975\u201384.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1812_CR55","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1161\/CIRCULATIONAHA.118.038065","volume":"139","author":"S Kufner","year":"2019","unstructured":"Kufner S, Joner M, Thannheimer A, Hoppmann P, Ibrahim T, Mayer K, et al. Ten-year clinical outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease. Circulation. 2019;139(3):325\u201333.","journal-title":"Circulation"},{"issue":"2","key":"1812_CR56","first-page":"139","volume":"13","author":"A Akinapelli","year":"2017","unstructured":"Akinapelli A, Chen JP, Roy K, Donnelly J, Dawkins K, Huibregtse B, et al. Current state of bioabsorbable polymer-coated drug-eluting stents. Curr Cardiol Rev. 2017;13(2):139\u201354.","journal-title":"Curr Cardiol Rev"},{"issue":"6","key":"1812_CR57","doi-asserted-by":"publisher","first-page":"E247","DOI":"10.1002\/ccd.25993","volume":"86","author":"GJ Wilson","year":"2015","unstructured":"Wilson GJ, Marks A, Berg KJ, Eppihimer M, Sushkova N, Hawley SP, et al. The SYNERGY biodegradable polymer everolimus eluting coronary stent: porcine vascular compatibility and polymer safety study. Catheter Cardiovasc Interv. 2015;86(6):E247\u201357.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"4","key":"1812_CR58","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1161\/CIRCINTERVENTIONS.113.000120","volume":"6","author":"MJ Eppihimer","year":"2013","unstructured":"Eppihimer MJ, Sushkova N, Grimsby JL, Efimova N, Kai W, Larson S, et al. Impact of stent surface on thrombogenicity and vascular healing: a comparative analysis of metallic and polymeric surfaces. Circ Cardiovasc Interv. 2013;6(4):370\u20137.","journal-title":"Circ Cardiovasc Interv"},{"key":"1812_CR59","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2011.12.016","volume":"59","author":"PI Meredith Am","year":"2012","unstructured":"Meredith Am PI, Verheye S, Dubois C, Dens J, Fajadet J, Carri\u00e9 D, et al. Primary endpoint results of the EVOLVE trial A randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J Am Coll Cardiol. 2012;59:1362\u201370.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1812_CR60","doi-asserted-by":"publisher","first-page":"e008152","DOI":"10.1161\/CIRCINTERVENTIONS.119.008152","volume":"12","author":"DJ Kereiakes","year":"2019","unstructured":"Kereiakes DJ, Windecker S, Jobe RL, Mehta SR, Sarembock IJ, Feldman RL, et al. Clinical outcomes following implantation of thin-strut, bioabsorbable polymer-coated, everolimus-eluting SYNERGY stents. Circ Cardiovasc Interv. 2019;12(9):e008152.","journal-title":"Circ Cardiovasc Interv"},{"issue":"2","key":"1812_CR61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.17925\/HI.2019.13.2.17","volume":"13","author":"JJ Wu","year":"2019","unstructured":"Wu JJ, Way JA, Brieger D. A review of the ultrathin orsiro biodegradable polymer drug-eluting stent in the treatment of coronary artery disease. Heart Int. 2019;13(2):17\u201324.","journal-title":"Heart Int"},{"issue":"8","key":"1812_CR62","doi-asserted-by":"publisher","first-page":"915","DOI":"10.4244\/EIJ-D-18-00336","volume":"14","author":"MM Kok","year":"2018","unstructured":"Kok MM, Zocca P, Buiten RA, Danse PW, Schotborgh CE, Scholte M, et al. Two-year clinical outcome of all-comers treated with three highly dissimilar contemporary coronary drug-eluting stents in the randomised BIO-RESORT trial. EuroIntervention. 2018;14(8):915\u201323.","journal-title":"EuroIntervention"},{"issue":"9960","key":"1812_CR63","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/S0140-6736(14)61038-2","volume":"384","author":"T Pilgrim","year":"2014","unstructured":"Pilgrim T, Heg D, Roffi M, T\u00fcller D, Muller O, Vuilliomenet A, et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet. 2014;384(9960):2111\u201322.","journal-title":"Lancet"},{"key":"1812_CR64","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.amsu.2018.12.003","volume":"38","author":"JJ Wu","year":"2018","unstructured":"Wu JJ, Way JAH, Kritharides L, Brieger D. Polymer-free versus durable polymer drug-eluting stents in patients with coronary artery disease: a meta-analysis. Ann Med Surg (Lond). 2018;38:13\u201321.","journal-title":"Ann Med Surg (Lond)"},{"issue":"6","key":"1812_CR65","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5694\/mja16.00444","volume":"205","author":"D Chen","year":"2016","unstructured":"Chen D, Jepson N. Coronary stent technology: a narrative review. Med J Aust. 2016;205(6):277\u201381.","journal-title":"Med J Aust"},{"issue":"3","key":"1812_CR66","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1517\/17425247.4.3.287","volume":"4","author":"I Tsujino","year":"2007","unstructured":"Tsujino I, Ako J, Honda Y, Fitzgerald PJ. Drug delivery via nano-, micro and macroporous coronary stent surfaces. Expert Opin Drug Deliv. 2007;4(3):287\u201395.","journal-title":"Expert Opin Drug Deliv"},{"key":"1812_CR67","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.actbio.2015.02.006","volume":"18","author":"S McGinty","year":"2015","unstructured":"McGinty S, Vo TTN, Meere M, McKee S, McCormick C. Some design considerations for polymer-free drug-eluting stents: a mathematical approach. Acta Biomater. 2015;18:213\u201325.","journal-title":"Acta Biomater"},{"issue":"3","key":"1812_CR68","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1755-5922.2010.00144.x","volume":"29","author":"L R\u00e4ber","year":"2011","unstructured":"R\u00e4ber L, Windecker S. Current status of drug-eluting stents. Cardiovasc Ther. 2011;29(3):176\u201389.","journal-title":"Cardiovasc Ther"},{"issue":"2","key":"1812_CR69","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10439-015-1380-x","volume":"44","author":"B O\u2019Brien","year":"2016","unstructured":"O\u2019Brien B, Zafar H, Ibrahim A, Zafar J, Sharif F. Coronary stent materials and coatings: a technology and performance update. Ann Biomed Eng. 2016;44(2):523\u201335.","journal-title":"Ann Biomed Eng"},{"issue":"6","key":"1812_CR70","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1161\/CIRCINTERVENTIONS.110.946426","volume":"3","author":"JA Ormiston","year":"2010","unstructured":"Ormiston JA, Abizaid A, Spertus J, Fajadet J, Mauri L, Schofer J, et al. Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Libert\u00e9 paclitaxel-eluting stent in de novo native coronary artery lesions. Circ Cardiovasc Interv. 2010;3(6):556\u201364.","journal-title":"Circ Cardiovasc Interv"},{"issue":"6","key":"1812_CR71","doi-asserted-by":"publisher","first-page":"721","DOI":"10.4244\/EIJV9I6A116","volume":"9","author":"A Abizaid","year":"2013","unstructured":"Abizaid A, Ormiston JA, Fajadet J, Mauri L, Schofer J, Verheye S, et al. Two-year follow-up of the NEVO ResElution-I(NEVO RES-I) trial: a randomised, multicentre comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Libert\u00e9 paclitaxel-eluting stent in de novo native coronary artery lesions. EuroIntervention. 2013;9(6):721\u20139.","journal-title":"EuroIntervention"},{"issue":"3","key":"1812_CR72","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S0952-7915(98)80172-6","volume":"10","author":"RT Abraham","year":"1998","unstructured":"Abraham RT. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol. 1998;10(3):330\u20136.","journal-title":"Curr Opin Immunol"},{"issue":"10","key":"1812_CR73","doi-asserted-by":"publisher","first-page":"6667","DOI":"10.4049\/jimmunol.177.10.6667","volume":"177","author":"M Klein","year":"2006","unstructured":"Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, Tertilt C, Bopp T, et al. Specific and redundant roles for NFAT transcription factors in the expression of mast cell-derived cytokines. J Immunol. 2006;177(10):6667.","journal-title":"J Immunol"},{"key":"1812_CR74","first-page":"343","volume-title":"Functionalised cardiovascular stents","author":"C Mcormick","year":"2018","unstructured":"Mcormick C. Index. In: Wall JG, Podbielska H, Wawrzy\u0144ska M, editors. Functionalised cardiovascular stents. Woodhead Publishing; 2018. p. 343\u201351."},{"issue":"23","key":"1812_CR75","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa012843","volume":"346","author":"M-C Morice","year":"2002","unstructured":"Morice M-C, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773\u201380.","journal-title":"N Engl J Med"},{"issue":"5","key":"1812_CR76","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jcin.2008.07.003","volume":"1","author":"JR Costa","year":"2008","unstructured":"Costa JR, Abizaid A, Costa R, Feres F, Tanajura LF, Abizaid A, et al. Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single De Novo coronary lesions: a first-in-human analysis of a third-generation drug-eluting stent system. JACC Cardiovasc Interv. 2008;1(5):545\u201351.","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"1812_CR77","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jcin.2009.02.009","volume":"2","author":"JR Costa","year":"2009","unstructured":"Costa JR, Abizaid A, Costa R, Feres F, Tanajura LF, Abizaid A, et al. 1-Year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial. JACC Cardiovasc Interv. 2009;2(5):422\u20137.","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Journal of Cardiothoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-022-01812-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-022-01812-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-022-01812-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T18:11:53Z","timestamp":1666721513000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiothoracicsurgery.biomedcentral.com\/articles\/10.1186\/s13019-022-01812-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1812"],"URL":"https:\/\/doi.org\/10.1186\/s13019-022-01812-y","relation":{},"ISSN":["1749-8090"],"issn-type":[{"value":"1749-8090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,4]]},"assertion":[{"value":"27 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Authors have given their consent of publication. No personal data of any individual has been used in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There is no conflict of interest among authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}